Semantic Scholar uses AI to extract papers important to this topic.
Summary The challenges of sepsis, the inflammatory cascade and multi organ failure have remained central to the practice of… Expand This paper examines the development and termination of nebacumab (Centoxin®), a human IgM monoclonal antibody (mAb) drug… Expand SummaryMonoclonal antibodies have been shown to reduce morbidity and mortality in selected subsets of patients with Gram-negative… Expand Meningococcal septic shock (MSS) has high mortality and morbidity rates. In addition to the traditional prompt antibiotics and… Expand ABSTRACT This note describes the binding specificities of four lipid A monoclonal antibodies (MAbs) including Centoxin (HA-1A… Expand Human IgM monoclonal antibody A6H4C5 was manufactured by Centocor (Malvern, PA) and used in clinical trials as HA-1A (Centoxin… Expand BACKGROUND
Antiendotoxin monoclonal antibodies are under investigation as adjunctive therapy for severe sepsis. One of these… Expand ObjectiveThe in vivo neutralizing activities of an anti-lipopolysaccharide (LPS) antibody HA-1A (Centoxin [Centocor, Malvern, PA… Expand The cytokines interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF alpha) have been… Expand SiR,—Gram-negative septicaemia is an important cause of mortality in hospital patients, especially when accompanied by… Expand